Company Update (NYSE:LLY): Eli Lilly loses Alimta drug patent case in Germany to Actavis

[Reuters – UK Focus] – Eli Lilly has lost a patent case in Germany over its blockbuster Alimta lung cancer drug to generic producer Actavis (NYSE: ACT – news) , hitting the U.S. . . . → Read More: Company Update (NYSE:LLY): Eli Lilly loses Alimta drug patent case in Germany to Actavis Similar Articles: Company Update (NYSE:LLY): Lilly delays submission to market once-daily diabetes drug Market Update (NYSE:LLY): FDA approves Boehringer-Lilly drug for type-2 diabetes patients Market Update: Gilead Sciences Inc (NASDAQ:GILD) – India rejects Gilead’s Hepatitis C drug patent request